Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.

Puglisi F, Minisini AM, De Angelis C, Arpino G.

Drugs. 2012 Jun 18;72(9):1175-93. doi: 10.2165/11634000-000000000-00000. Review.

PMID:
22686613
2.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

3.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
4.

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.

Wilks ST.

Breast. 2015 Oct;24(5):548-55. doi: 10.1016/j.breast.2015.06.002. Epub 2015 Jul 15. Review.

5.

Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.

Huang Y, Fu P, Fan W.

Curr Drug Targets. 2013 Jul;14(8):889-98. Review.

PMID:
23531110
6.

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Zardavas D, Cameron D, Krop I, Piccart M.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e2. Review.

7.

Targeting HER2 for the treatment of breast cancer.

Rimawi MF, Schiff R, Osborne CK.

Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127. Review.

PMID:
25587647
8.

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.

Mohd Sharial MS, Crown J, Hennessy BT.

Ann Oncol. 2012 Dec;23(12):3007-16. doi: 10.1093/annonc/mds200. Epub 2012 Aug 2. Review.

9.

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.

Mol Cancer Ther. 2010 Jun;9(6):1489-502. doi: 10.1158/1535-7163.MCT-09-1171. Epub 2010 May 25. Erratum in: Mol Cancer Ther. 2011 Nov;10(11):2211.

10.

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.

Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy BT, Eustace AJ.

Breast Cancer Res Treat. 2015 Jan;149(2):373-83. doi: 10.1007/s10549-014-3239-5. Epub 2014 Dec 21.

PMID:
25528022
11.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
12.

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.

Gradishar WJ.

Ann Oncol. 2013 Oct;24(10):2492-500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4. Review.

PMID:
23827380
13.

Mechanisms of lapatinib resistance in HER2-driven breast cancer.

D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R.

Cancer Treat Rev. 2015 Dec;41(10):877-83. doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8. Review.

PMID:
26276735
14.

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini KS, Azim HA Jr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart M.

Breast. 2011 Oct;20 Suppl 3:S20-7. doi: 10.1016/S0960-9776(11)70289-2. Review.

PMID:
22015288
15.

Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

Sachdev JC, Jahanzeb M.

Clin Breast Cancer. 2012 Feb;12(1):19-29. doi: 10.1016/j.clbc.2011.07.001. Epub 2011 Sep 8. Review.

PMID:
21903480
16.

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.

Tsang RY, Finn RS.

Br J Cancer. 2012 Jan 3;106(1):6-13. doi: 10.1038/bjc.2011.516. Review.

17.

HER2 aberrations in cancer: implications for therapy.

Yan M, Parker BA, Schwab R, Kurzrock R.

Cancer Treat Rev. 2014 Jul;40(6):770-80. doi: 10.1016/j.ctrv.2014.02.008. Epub 2014 Mar 12.

PMID:
24656976
18.
19.

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.

Creedon H, Byron A, Main J, Hayward L, Klinowska T, Brunton VG.

Biochem Soc Trans. 2014 Aug;42(4):822-30. doi: 10.1042/BST20140109. Review.

PMID:
25109964
20.

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Review.

PMID:
23881722

Supplemental Content

Support Center